146 related articles for article (PubMed ID: 19615550)
1. Systemic progression following complete cutaneous remission under bexarotene treatment for tumor-stage mycosis fungoides.
Amitay-Laish I; David M; Hodak E
J Am Acad Dermatol; 2009 Aug; 61(2):361-2. PubMed ID: 19615550
[No Abstract] [Full Text] [Related]
2. Poikilodermatous Mycosis Fungoides - Rare Entity, Different Treatment Modalities.
Jerković Gulin S; Čeović R; Ilić I; Bradamante M; Bukvić Mokos Z; Kostović K
Acta Dermatovenerol Croat; 2018 Apr; 26(1):48-52. PubMed ID: 29782300
[TBL] [Abstract][Full Text] [Related]
3. Leonine facies (LF) and mycosis fungoides (MF): A single-center study and systematic review of the literature.
Brown DN; Wieser I; Wang C; Dabaja BS; Duvic M
J Am Acad Dermatol; 2015 Dec; 73(6):976-86. PubMed ID: 26476898
[TBL] [Abstract][Full Text] [Related]
4. Case experience of 308-nm excimer laser therapy compatibility with PUVA and oral bexarotene for the treatment of cutaneous lesions in mycosis fungoides.
Huang J; Cowper S; Moss J; Girardi M
J Drugs Dermatol; 2013 Apr; 12(4):487-9. PubMed ID: 23652902
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056).
Whittaker S; Ortiz P; Dummer R; Ranki A; Hasan B; Meulemans B; Gellrich S; Knobler R; Stadler R; Karrasch M
Br J Dermatol; 2012 Sep; 167(3):678-87. PubMed ID: 22924950
[TBL] [Abstract][Full Text] [Related]
6. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
[TBL] [Abstract][Full Text] [Related]
7. Mycosis fungoides with follicular mucinosis displaying aggressive tumor-stage transformation : successful treatment using radiation therapy plus oral bexarotene combination therapy.
Apisarnthanarax N; Ha CS; Duvic M
Am J Clin Dermatol; 2003; 4(6):429-33. PubMed ID: 12762834
[TBL] [Abstract][Full Text] [Related]
8. Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB.
D'Acunto C; Gurioli C; Neri I
J Dermatolog Treat; 2010 Jan; 21(1):45-8. PubMed ID: 19603308
[TBL] [Abstract][Full Text] [Related]
9. Mycosis fungoides palmaris et plantaris--an unusual variant of cutaneous T-cell lymphoma.
Topf S; Lüftl M; Neisius U; Brabletz T; Simon M; Schuler G; Schultz ES
Eur J Dermatol; 2006; 16(1):84-6. PubMed ID: 16436350
[TBL] [Abstract][Full Text] [Related]
10. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
11. Induction of complete remission of advanced stage mycosis fungoides by allogeneic hematopoietic stem cell transplantation.
Masood N; Russell KJ; Olerud JE; Sabath DE; Sale GE; Doney KC; Flowers ME; Fefer A; Thompson JA
J Am Acad Dermatol; 2002 Jul; 47(1):140-5. PubMed ID: 12077596
[TBL] [Abstract][Full Text] [Related]
12. Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.
Hughes CF; Newland K; McCormack C; Lade S; Prince HM
Australas J Dermatol; 2016 Aug; 57(3):182-91. PubMed ID: 25988337
[TBL] [Abstract][Full Text] [Related]
13. Folliculotropic mycosis fungoides presenting as non-inflammatory scarring scalp alopecia associated with comedo-like lesions.
Errichetti E; Chiacchio R; Piccirillo A
Int J Dermatol; 2016 Jan; 55(1):e40-1. PubMed ID: 26518355
[No Abstract] [Full Text] [Related]
14. Erythema gyratum repens-like eruptions with large cell transformation in a patient with mycosis fungoides.
Holcomb M; Duvic M; Cutlan J
Int J Dermatol; 2012 Oct; 51(10):1231-3. PubMed ID: 21726213
[No Abstract] [Full Text] [Related]
15. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
16. Local radiation and phototherapy are the most cost-effective treatments for stage IA mycosis fungoides: A comparative decision analysis model in the United States.
Xia FD; Ferket BS; Huang V; Stern RS; Wu PA
J Am Acad Dermatol; 2019 Feb; 80(2):485-492.e4. PubMed ID: 30081119
[TBL] [Abstract][Full Text] [Related]
17. Folliculotropic mycosis fungoides: clinicopathological features and outcome in a series of 20 cases.
Muniesa C; Estrach T; Pujol RM; Gallardo F; Garcia-Muret P; Climent J; Servitje O
J Am Acad Dermatol; 2010 Mar; 62(3):418-26. PubMed ID: 20079954
[TBL] [Abstract][Full Text] [Related]
18. [Bexarotene therapy in folliculotropic cutaneous T-cell lymphoma].
Drugeon C; Charlat I; Boulinguez S; Viraben R
Ann Dermatol Venereol; 2007; 134(8-9):639-43. PubMed ID: 17925686
[TBL] [Abstract][Full Text] [Related]
19. Bexarotene plus PUVA plus radiation combination therapy for mycosis fungoides.
Coors E
Dermatol Clin; 2008 Jan; 26 Suppl 1():33-5. PubMed ID: 18405185
[No Abstract] [Full Text] [Related]
20. Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma.
Shapiro M; Rook AH; Lehrer MS; Junkins-Hopkins JM; French LE; Vittorio CC
J Am Acad Dermatol; 2002 Dec; 47(6):956-61. PubMed ID: 12451388
[No Abstract] [Full Text] [Related]
[Next] [New Search]
